| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5946332 | Atherosclerosis | 2013 | 7 Pages |
Abstract
HMGB1 serves as an endogenous mediator of inflammation and lesion formation via the TLR9 pathway in response to vascular injury. Blockade of HMGB1 and/or TLR9 may represent a novel approach to treating atherosclerosis.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Yoichiro Hirata, Hirotsugu Kurobe, Mayuko Higashida, Daiju Fukuda, Michio Shimabukuro, Kimie Tanaka, Yasutomi Higashikuni, Tetsuya Kitagawa, Masataka Sata,